Get the EXEL Research Report and
Also Receive Our Top Trades for 2016!

Exelixis, Inc.

On March 6th, the company announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma (HCC). This information was posted to FDA’s website on March 4, 2017 and can be accessed here. CABOMETYX generated $44.7 million and $93.5 million in net product revenue during the fourth quarter and full year of 2016, respectively. COMETRIQ® (cabozantinib) capsules for the treatment of medullary thyroid cancer genera … (See Research Report)
Download Research Report
on EXEL Now